No major sleep guideline (AASM 2017/2021, ACP 2016, or VA/DoD 2019/2025) recommends gabapentin for primary chronic insomnia, and zero placebo-controlled RCTs have tested it in diagnosed chronic insomnia disorder (very low certainty overall). While off-label bedtime gabapentin (100 to 600 mg) increases deep slow-wave sleep (Stage N3) and reduces wake after sleep onset (WASO by -35 to -62.5 minutes) in artificial 5-hour phase-advance models of transient sleep disruption (Rosenberg 2014; Furey 2014), it does not shorten sleep-onset latency (SOL) and carries significant harms: a +84% increase in the apnea-hypopnea index (AHI 22.4 vs 12.2/hr) and +91% jump in oxygen desaturation index after a single 300 mg bedtime dose in older men (Piovezan 2017, NNH 4), an FDA 2019 respiratory depression warning (opioid co-prescribing death aOR 1.49 to 1.58, Gomes 2017), dose-related dizziness (NNH 8), peripheral edema (NNH 20), weight gain, and a withdrawal syndrome. Fishtown Medicine reserves gabapentin for insomnia driven by restless legs syndrome, neuropathic pain, or vasomotor night waking, in Pennsylvania and New Jersey only with an in-person visit every six months.
TL;DR: Gabapentin (100 to 600 mg off-label at bedtime; up to 1,800 mg/day in pain/recovery trials) is one of the few drugs that increases deep slow-wave sleep (Stage N3), which is why it gets prescribed so often for sleep. Yet the PICO evidence shows why it is never a casual sleeping pill:
- Zero chronic-insomnia RCTs & zero guideline endorsement (AASM, ACP, VA/DoD): No sleep guideline recommends gabapentin for primary chronic insomnia (very low certainty). Zero double-blind, placebo-controlled RCTs have tested gabapentin in adults with chronic insomnia disorder. The two largest sleep trials (Rosenberg 2014, n = 377; Furey 2014, n = 256) put occasional poor sleepers to bed 5 hours early (phase-advance model). That cut night waking (WASO) by 35 to 62.5 minutes with zero effect on time to fall asleep (SOL). For primary chronic insomnia, multicomponent CBT-I is the strong first-line recommendation (SOL -19 min, WASO -26 min, lasting at 12 months).
- The sleep apnea (+84% AHI) and FDA 2019 breathing warnings (Piovezan 2017; Gomes 2017): In a double-blind crossover trial (Piovezan et al., J Sleep Res 2017), a single 300 mg bedtime dose of gabapentin raised the apnea-hypopnea index (AHI) by +84% (22.4 vs 12.2 events/hr, NNH = 4) and oxygen drops (ODI) by +91% during NREM sleep. The FDA (2019) and 2023 AGS Beers Criteria warn against serious breathing slowdowns when gabapentin is combined with opioids (49% to 58% higher odds of opioid-related death, Gomes et al., PLoS Med 2017), other sedatives, COPD, or older age.
- When gabapentin fits (RLS, nerve pain, hot flashes) and how we prescribe it: Gabapentin makes sense when insomnia shares a root cause it directly treats, such as restless legs syndrome (RLS), nerve pain, or menopausal night sweats. Because of its breathing, weight-gain (>= 5% body weight in 57% at 12 months), and rebound withdrawal risks, Fishtown Medicine prescribes gabapentin in Pennsylvania and New Jersey only, with an in-person visit every 6 months, kidney (eGFR) dose checks, and sleep apnea screening.
Gabapentin was treated for two decades as a harmless, unscheduled alternative to sleeping pills. That reputation grew by comparing it with benzodiazepines instead of testing it in chronic insomnia. When you read the sleep-lab (PSG) trials and safety studies, a clear boundary emerges.
How does gabapentin affect sleep architecture (Slow-Wave Sleep vs. Sleep Onset)?
Gabapentin binds the alpha-2-delta (\alpha_2\delta) subunit of voltage-gated calcium channels, quieting excitatory nerve release and increasing deep slow-wave sleep (Stage N3) and sleep maintenance (WASO), without shortening the time it takes to fall asleep (SOL).123
Despite its name, gabapentin does not bind GABA-A or GABA-B receptors:
- Why deep sleep rises (Foldvary-Schaefer et al., Epilepsia 2002; Yeh et al., Sleep Med 2021): Benzodiazepines and Z-drugs act on GABA-A receptors, which speeds up sleep onset while flattening the slow brain waves that generate restorative Stage N3 slow-wave sleep (SWS). By calming calcium entry at \alpha_2\delta channels, gabapentin (1,500 to 1,800 mg/day in healthy adults, Foldvary-Schaefer 2002) and related drugs increase SWS across 18 sleep-lab RCTs (Yeh et al., 2021), fibromyalgia (Roth 2012), and restless legs syndrome (Winkelman 2011, N3 +12.1 min).4567
- The clinical gap: Whether drug-induced gains in SWS improve daytime focus or health outcomes in primary chronic insomnia has never been proven in a trial.12
What do sleep guidelines and clinical trials show (Gabapentin vs. Placebo and CBT-I)?
No major sleep guideline (AASM 2017/2021, ACP 2016, or VA/DoD 2019/2025) recommends or grades gabapentin for chronic insomnia (very low certainty). Zero placebo-controlled RCTs have tested gabapentin in chronic insomnia disorder, and a 2022 review (Hong et al., Mol Psychiatry) concluded gabapentin should only be used when a separate condition justifies it.189101112
| Trial or Guideline | Design & Population (n) | Gabapentin Dose | Sleep Maintenance (WASO), Onset (SOL), & Total Sleep (TST) | Key Clinical Limit |
|---|---|---|---|---|
| AASM 2017/2021, ACP 2016, & VA/DoD 2019/2025 Guidelines | Clinical practice guidelines | Not graded (AASM excluded Lo 2010 due to open-label design, n = 18, no placebo)813 | No recommendation for gabapentin in chronic insomnia; STRONG recommendation for CBT-I (49 RCTs, moderate certainty).891011 | Lack of a guideline grade reflects missing primary insomnia RCTs instead of approval.811 |
| Single-Night 5-Hr Phase Advance (Rosenberg et al., JCSM 2014) | Double-blind, 3-arm PSG RCT (n = 377 occasional poor sleepers put to bed 5 hrs early) | Single dose: 250 mg or 500 mg vs placebo | WASO: 135.7 min (placebo) vs 100.7 min (250 mg, -35.0 min / -26%) vs 73.2 min (500 mg, -62.5 min / -46%); TST +45 & +67 min; SWS 12.6% -> 15.4% -> 17.0%; SOL unchanged.2 | Artificial jet-lag (5-hr phase advance) model in healthy adults; did not enroll chronic insomnia patients.2 |
| 28-Day 5-Hr Phase Advance (Furey et al., JCSM 2014) | Double-blind PSG RCT (n = 256 occasional poor sleepers) | 250 mg or 500 mg nightly for 28 days | WASO Day 1: 107.0 vs 149.1 min (-42.1 min / -28%); Day 28: 113.6 vs 152.3 min (-38.7 min / -25%); TST +63.7 & +46.2 min; no tolerance at Day 28.3 | Longest sleep RCT is only 28 days and did not enroll chronic insomnia patients.3 |
| Alcohol Dependence + Insomnia (Brower et al., 2008; Mason et al., JAMA Intern Med 2014; Hong et al., Mol Psychiatry 2022) | Double-blind RCTs (n = 21 for 6 wks; n = 150 for 12 wks; pooled n = 171 in Hong 2022) | Up to 1,500 to 1,800 mg at bedtime | Brower 2008 showed zero PSG or diary sleep gain vs placebo; Mason 2014 (1,800 mg) improved PSQI by -1.5 points; pooled review (Hong 2022, n = 171) showed no sleep scale benefit.121415 | Hong et al. (2022) judged insomnia evidence inconclusive and advised against use without strong comorbidity justification.12 |
| Comorbid Medical Illness & Hot Flashes (Liu et al., Front Neurol 2017; Pinkerton 2014; Yurcheshen 2009) | Meta-analysis & hot-flash RCTs | 300 to 1,800 mg/day | Improved secondary sleep scores in nerve pain, RLS, and menopausal night waking.161718 | Sleep gains follow from fewer hot flashes, less pain, or calmer legs, with high dropout rates at ~1,800 mg/day.1617 |
| First-Line Benchmark: Multicomponent CBT-I (Trauer et al., Ann Intern Med 2015; Gao 2022; Morin & Buysse, NEJM 2024) | 20 RCT meta-analysis (n = 1,162) & 61 RCT network (n = 11,571) in chronic insomnia | 4 to 8 structured sessions | SOL -19.0 min, WASO -26.0 min, sleep efficiency +9.9%; 60% to 70% response and 40% to 45% remission lasting at 12 months.192021 | Across 23 RCTs vs sleep pills (Zhang 2022; Perlis 2022), only CBT-I keeps working after stopping treatment.2223 |
Does gabapentin worsen sleep apnea (OSA), and what is the FDA 2019 breathing warning?
Yes. In a randomized, double-blind crossover trial (Piovezan et al., J Sleep Res 2017), a single 300 mg bedtime dose of gabapentin raised the apnea-hypopnea index (AHI) by +84% (22.4 vs 12.2 events/hr, NNH = 4) and the oxygen desaturation index (ODI) by +91%. In December 2019, the FDA issued a class-wide respiratory warning for gabapentin and pregabalin.242526
1. Obstructive Sleep Apnea (OSA) Worsening (Piovezan et al., J Sleep Res 2017)
Many adults with broken sleep have undiagnosed obstructive sleep apnea:
- The +84% AHI crossover signal (Piovezan et al., 2017, n = 8 non-obese older men without known OSA): After a single 300 mg bedtime dose of gabapentin, sleep-lab testing showed the apnea-hypopnea index (AHI) jumped from 12.2 +/- 4.3 on placebo to 22.4 +/- 6.1 events/hour (+10.2 events/hr or +84% jump; d = 0.67; NNH = 4 for pushing AHI into the moderate-to-severe range).24
- +91% more oxygen drops: The oxygen desaturation index (ODI) rose from 10.8 to 20.6 drops/hour (+91%), concentrated during NREM sleep and back (supine) sleeping, likely by relaxing upper-airway muscle tone.24 No RCT has yet tested gabapentin in patients with established severe OSA, and gabapentin weight gain can worsen OSA further over time (Rehim et al., Epilepsia 2026).2427
- Contrast with targeted sleep drugs (Messineo AJRCCM 2024; Kishi 2026; Mason Cochrane 2015; Carter 2018): Across reviews of 32 RCTs in OSA, dual orexin blockers (lemborexant, daridorexant) and standard-dose zolpidem / zopiclone did not raise AHI (AHI -1.4 events/hr, Messineo 2024). That makes gabapentin's +84% AHI jump a distinct airway concern.28293031
2. FDA 2019 Respiratory Warning & Opioid Co-Prescribing Mortality (Gomes 2017; Hahn 2022)
- FDA & CDC safety data (Kuehn JAMA 2022; Fernández-Liz 2022): In December 2019, the FDA mandated warnings for serious breathing problems with gabapentin (49 initial reports, 12 deaths, 92% having at least one risk factor: opioids, other sedatives, COPD, or older age).2526 By 2019-2020, CDC data found gabapentin in ~10% of US overdose deaths (5,687 of 58,362), with ~90% also involving opioids.2532
- Mortality odds (Gomes et al., PLoS Med 2017; Hahn et al., Front Pharmacol 2022; Hart et al., JAGS 2025): In a nested case-control study (Gomes et al., 2017, 1,256 cases and 4,619 controls), combining gabapentin with an opioid raised the odds of opioid-related death by 49% (aOR 1.49, 95% CI 1.18 to 1.88), rising to 58% (aOR 1.58) at gabapentin >= 1,800 mg/day.33 Across observational studies (Hahn et al., 2022), combination therapy carried a breathing slowdown OR of 1.71 (95% CI 1.31 to 2.24) and death OR of 2.76.34 In Medicare patients (Hart 2025), gabapentin + opioids doubled all-cause death (HR 2.03) compared with duloxetine + opioids.35 The 2023 AGS Beers Criteria issue a strong recommendation to avoid combining gabapentinoids with opioids.36 (Fishtown Medicine does not prescribe opioids for any condition, and we never add gabapentin to an outside opioid or sedative regimen.)
What are the dose-dependent side effects, weight gain, and withdrawal risks?
Across FDA trials and Cochrane reviews (Wiffen et al., 2017; Meaadi et al., 2023), gabapentin causes dose-related dizziness (NNH 8), drowsiness (NNH 11), unsteady walking (NNH 8.5), ankle swelling (NNH 20), and weight gain (>= 5% body weight in 57% of adults at 12 months), plus rebound insomnia if stopped suddenly.37383940
| Side Effect / Safety Domain | Trial Rate (Gabapentin vs. Placebo) | Relative Risk (RR) & Number Needed to Harm (NNH) | Clinical Context & Care |
|---|---|---|---|
| Dizziness (FDA Label; Cochrane 2017) | 28% vs 8% (FDA trials); 19% vs 6.6% (Cochrane >= 1,200 mg/day) | NNH = 83739 | Top cause of falls in older adults; start low (100 mg) and check kidney function (eGFR).37 |
| Somnolence / Next-Day Drowsiness (FDA Label; Cochrane 2017) | 21% vs 5% (FDA trials); 14% vs 5.2% (Cochrane) | RR 2.8 (NNH = 11)3739 | Compounds with alcohol, antihistamines, Z-drugs, or benzodiazepines.3739 |
| Ataxia / Unsteady Walking (FDA Label; Cochrane 2017) | 3% vs 0% (FDA label); gait trouble in Cochrane | NNH = 8.53739 | Raises nighttime bathroom fall risk.39 |
| Peripheral Edema / Ankle Swelling (FDA Label; Cochrane 2017) | 8% vs 2% (FDA trials); 6.7% vs 1.7% (Cochrane) | RR 4.1 (NNH = 20)3739 | Calcium-channel vessel dilation in the legs; clears when gabapentin is tapered off.3739 |
| Weight Gain (Meaadi 2023; Medici 2016; Kaye 2025) | Meta-analytic NNH = 28 in short RCTs; 57% gained >= 5% body weight and 23% gained >= 10% over 12 months (n = 44 cohort) | NNH = 28 (short-term); 57% (>= 5% wt gain at 1 yr)404142 | Dose-dependent appetite and fluid shift that can worsen metabolic health and OSA.4142 |
| Stopping Due to Side Effects (FDA Label; Cochrane) | 16% vs 9% (FDA trials); any side effect 63% vs 49% (Cochrane) | Any AE NNH = 7373839 | High drop-out rate at doses >= 1,200 to 1,800 mg/day (Liu 2017).1639 |
Kidney Clearance (eGFR Dose Rule) and Rebound Withdrawal
- 100% Kidney Excretion (FDA Label): Gabapentin is not broken down by the liver and leaves unchanged in urine.3738 Lower kidney function (check your Cystatin C and eGFR) causes gabapentin to build up, raising drowsiness, unsteadiness, and breathing risk unless the dose is lowered when eGFR < 60 mL/min/1.73m².37
- Sudden Stopping & Rebound Insomnia: Stopping gabapentin suddenly after months of nightly use can trigger rebound insomnia, anxiety, sweating, nausea, tremor, rapid heart rate, and rarely seizures.3842 Because the first 3 to 5 nights off gabapentin feel worse than baseline, many people think they cannot sleep without it. Tapering over 1 to 2+ weeks prevents withdrawal.
Evidence-Based Treatment
Dr. Ash reviews the research - and applies it to your specific biology.
How Fishtown Medicine prescribes gabapentin (and when CBT-I comes first)
At Fishtown Medicine, gabapentin is placed in our tethered medication group alongside scheduled drugs:
- Prescribed in Pennsylvania and New Jersey only, with an in-person visit every 6 months: Several states classify gabapentin as a Schedule V controlled substance or require state monitoring (PDMP) due to misuse risk (Kuehn JAMA 2022). We require a written clinical reason, an eGFR check, sleep apnea screening, and a 6-month in-person visit in PA or NJ.25
- When gabapentin is the right tool: When insomnia is driven by restless legs syndrome (RLS), nerve pain that wakes you at night, or menopausal night sweats (Pinkerton 2014), a low bedtime dose (100 to 300 mg, up to 600 mg) can treat two problems with one drug.1717
- When CBT-I comes first: For primary chronic insomnia without nerve pain or RLS, multicomponent CBT-I (Scott JAMA Intern Med 2025; Bai 2024; Xu 2024) is our first-line care.91943
Guidance from the Clinic
Actionable Steps
Safety checklist if you take or are considering gabapentin for sleep:
- Name the Root Driver (RLS, Nerve Pain, or Hot Flashes vs. Primary Insomnia): If you have chronic insomnia without restless legs, nerve pain, or night sweats, start with multicomponent CBT-I (SOL -19 min, WASO -26 min), which has 49+ RCTs and lasting 12-month remission (Edinger 2021; Trauer 2015).
- Screen for Obstructive Sleep Apnea First (Piovezan 2017 Rule): A single 300 mg bedtime dose raised AHI by +84% and oxygen drops by +91% (NNH = 4). Rule out or treat sleep apnea before using gabapentin at night, particularly if you snore or wake unrefreshed.
- Never Combine Gabapentin with Opioids or Multiple Sedatives (FDA 2019 & Beers 2023): Co-prescribing with opioids raises opioid-related death odds by 49% to 58% (Gomes 2017) and breathing slowdown odds by 71% (Hahn 2022).
- Check Kidney Function (eGFR) and Track Weight & Ankle Swelling: Gabapentin is 100% cleared by the kidneys and carries a NNH = 20 for ankle swelling and 57% rate of >= 5% weight gain at 12 months (Meaadi 2023; Medici 2016). Use the lowest effective bedtime dose (100 to 300 mg).
- Taper Gradually (Never Stop Cold Turkey): If you and your doctor decide to stop nightly gabapentin, taper down over 1 to 2+ weeks to avoid rebound insomnia and withdrawal. Start an intake with Dr. Ash to review your sleep plan.
Key Takeaways
- No major sleep guideline (AASM 2017/2021, ACP 2016, VA/DoD 2019/2025) recommends gabapentin for chronic insomnia (very low certainty), and zero placebo-controlled RCTs exist in chronic insomnia disorder.18101112
- Gabapentin increases deep slow-wave sleep (Stage N3) and cuts WASO (-35 to -62.5 min) in 5-hour phase-advance models (Rosenberg 2014; Furey 2014), without helping you fall asleep faster (SOL).234
- A single 300 mg bedtime dose raised the apnea-hypopnea index (AHI) by +84% and oxygen drops (ODI) by +91% (NNH = 4, Piovezan 2017), and the FDA 2019 warning highlights serious breathing risk with opioids (death aOR 1.49 to 1.58, Gomes 2017), sedatives, COPD, or older age.24253336
- Expect dose-related dizziness (NNH 8), drowsiness (NNH 11), ankle swelling (NNH 20), and weight gain (>= 5% in 57% at 12 months), and always taper gradually to avoid rebound insomnia.373941
- Use CBT-I first-line for primary chronic insomnia, and save gabapentin for insomnia driven by RLS, nerve pain, or night sweats (PA and NJ only at Fishtown Medicine, with 6-month in-person follow-up).1919
Related at Fishtown Medicine
- CBT-I for insomnia
- Hydroxyzine for sleep
- Is it insomnia or sleep apnea?
- Z-drugs for insomnia
- Doxepin for sleep
- Insomnia
Scientific References
- Krystal AD, Prather AA, Ashbrook LH. "The assessment and management of insomnia: an update." World Psychiatry. 2019;18(3):337-352. DOI
- Rosenberg RP, Hull SG, Lankford DA, et al. "A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter, Polysomnographic Study of Gabapentin in Transient Insomnia Induced by Sleep Phase Advance." Journal of Clinical Sleep Medicine. 2014;10(10):1093-1100. PubMed
- Furey SA, Hull SG, Leibowitz MT, Jayawardena S, Roth T. "A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 28-Day, Polysomnographic Study of Gabapentin in Transient Insomnia Induced by Sleep Phase Advance." Journal of Clinical Sleep Medicine. 2014;10(10):1101-1109. PubMed
- Foldvary-Schaefer N, De Leon Sanchez I, Karafa M, Mascha E, Dinner D, Morris HH. "Gabapentin Increases Slow-Wave Sleep in Normal Adults." Epilepsia. 2002;43(12):1493-1497. DOI
- Yeh WC, Lu SR, Wu MN, et al. "The Impact of Antiseizure Medications on Polysomnographic Parameters: A Systematic Review and Meta-Analysis." Sleep Medicine. 2021;81:319-328. PubMed
- Roth T, Lankford DA, Bhadra P, Whalen E, Resnick EM. "Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: A randomized, placebo-controlled, 2-way crossover polysomnography study." Arthritis Care & Research. 2012;64(4):597-606. DOI
- Winkelman JW, Bogan RK, Schmidt MH, et al. "Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome." Movement Disorders. 2011;26(11):2065-2072. DOI
- Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. "Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline." Journal of Clinical Sleep Medicine. 2017;13(2):307-349. PMC
- Edinger JD, Arnedt JT, Bertisch SM, et al. "Behavioral and Psychological Treatments for Chronic Insomnia Disorder in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline." Journal of Clinical Sleep Medicine. 2021;17(2):255-262. PMC
- Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. "Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians." Annals of Internal Medicine. 2016;165(2):125-133. DOI
- Sharafkhaneh A, Thomas A, Ulmer C, et al. "VA/DoD Clinical Practice Guideline for the Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea (Insomnia/OSA)." Department of Veterans Affairs & Department of Defense. 2025. Guideline PDF
- Hong JSW, Atkinson LZ, Al-Juffali N, et al. "Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale." Molecular Psychiatry. 2022;27(3):1339-1349. DOI
- Lo HS, Yang CM, Lo HG, Lee CY, Ting H, Tzang BS. "Treatment Effects of Gabapentin for Primary Insomnia." Clinical Neuropharmacology. 2010;33(2):84-90. PubMed
- Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA. "A Randomized Double-Blind Pilot Trial of Gabapentin Versus Placebo to Treat Alcohol Dependence and Comorbid Insomnia." Alcoholism: Clinical and Experimental Research. 2008;32(8):1429-1438. PubMed
- Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. "Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial." JAMA Internal Medicine. 2014;174(1):70-77. DOI
- Liu GJ, Karim MR, Xu LL, Wang YH,yda M. "Efficacy and Tolerability of Gabapentin in Adults With Sleep Disturbance in Medical Illness: A Systematic Review and Meta-Analysis." Frontiers in Neurology. 2017;8:316. PubMed
- Pinkerton JV, Kagan R, Portman D, Sathyanarayana R, Sweeney M. "Phase 3 Randomized Controlled Study of Gastroretentive Gabapentin for the Treatment of Moderate-to-Severe Hot Flashes in Menopause." Menopause. 2014;21(6):567-573. PubMed
- Yurcheshen ME, Guttuso T, McDermott M, Holloway RG, Perlis M. "Effects of Gabapentin on Sleep in Menopausal Women with Hot Flashes as Measured by a Pittsburgh Sleep Quality Index Factor Scoring Model." Journal of Women's Health. 2009;18(9):1355-1360. DOI
- Trauer JM, Qian MY, Doyle JS, Rajaratnam SM, Cunnington D. "Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-Analysis." Annals of Internal Medicine. 2015;163(3):191-204. PubMed
- Gao Y, Ge L, Liu M, et al. "Comparative Efficacy and Acceptability of Cognitive Behavioral Therapy Delivery Formats for Insomnia in Adults: A Systematic Review and Network Meta-Analysis." Sleep Medicine Reviews. 2022;64:101648. PubMed
- Morin CM, Buysse DJ. "Management of Insomnia." The New England Journal of Medicine. 2024;391(3):247-258. DOI
- Zhang Y, Ren R, Yang L, et al. "Comparative Efficacy and Acceptability of Psychotherapies, Pharmacotherapies, and Their Combination for the Treatment of Adult Insomnia: A Systematic Review and Network Meta-Analysis." Sleep Medicine Reviews. 2022;65:101687. PubMed
- Perlis ML, Posner D, Riemann D, Bastien CH, Teichtenberg L, Thase M. "Insomnia." The Lancet. 2022;400(10357):1047-1060. PubMed
- Piovezan RD, Kase C, Moizinho R, Tufik S, Poyares D. "Gabapentin Acutely Increases the Apnea-Hypopnea Index in Older Men: Data From a Randomized, Double-Blind, Placebo-Controlled Study." Journal of Sleep Research. 2017;26(2):166-170. PubMed
- Kuehn BM. "Growing Role of Gabapentin in Opioid-Related Overdoses Highlights Misuse Potential and Off-label Prescribing Practices." JAMA. 2022;328(13):1283-1285. DOI
- Fernández-Liz E, Barceló-Colomer ME, Gómez-Ganda L, et al. "Prevalence of Gabapentinoids and Central Nervous System Depressant Drugs, and Their Association with Risk Factors for Respiratory Depression in Primary Care Patients." Clinical Drug Investigation. 2022;42(5):417-426. DOI
- Rehim ED, Vendrame M, Devinsky O. "Obstructive sleep apnea in people with epilepsy: Modifying risk." Epilepsia. 2026. DOI
- Mason M, Cates CJ, Smith I. "Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea." Cochrane Database of Systematic Reviews. 2015;(7):CD011090. DOI
- Messineo L, Sands SA, Labarca G. "Hypnotics on Obstructive Sleep Apnea Severity and Endotypes: A Systematic Review and Meta-Analysis." American Journal of Respiratory and Critical Care Medicine. 2024;210(9):1135-1148. PubMed
- Kishi T, Ikuta T, Sakuma K, et al. "Comparative Effects of Hypnotic Agents on Sleep Architecture and Respiratory Outcomes in Obstructive Sleep Apnea: A Systematic Review and Network Meta-Analysis." Psychiatry and Clinical Neurosciences. 2026. PubMed
- Carter SG, Carberry JC, Cho G, et al. "Effect of 1 month of Zopiclone on Obstructive Sleep Apnoea Severity and Symptoms: A Randomised Controlled Trial." European Respiratory Journal. 2018;52(1):1800149. PubMed
- Kuehn BM. "Gabapentin Increasingly Implicated in Overdose Deaths." JAMA. 2022;327(24):2387. DOI
- Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. "Gabapentin, Opioids, and the Risk of Opioid-Related Death: A Population-Based Nested Case-Control Study." PLoS Medicine. 2017;14(10):e1002396. PubMed
- Hahn J, Jo Y, Yoo SH, Shin J, Yu YM, Ah YM. "Risk of Major Adverse Events Associated With Gabapentinoid and Opioid Combination Therapy: A Systematic Review and Meta-Analysis." Frontiers in Pharmacology. 2022;13:1009950. PubMed
- Hart LA, Vo S, Hanlon JT, Schmader KE, Gray SL. "Medication Use Quality and Safety in Older Adults: 2023 Update." Journal of the American Geriatrics Society. 2025;73(2):365-375. DOI
- 2023 American Geriatrics Society Beers Criteria Update Expert Panel. "American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults." Journal of the American Geriatrics Society. 2023;71(7):2052-2081. DOI
- Food and Drug Administration. "Neurontin (Gabapentin) Prescribing Information." Updated July 2026. DailyMed
- Food and Drug Administration. "Gabapentin Capsules Prescribing Information." Updated May 2025. DailyMed
- Wiffen PJ, Derry S, Bell RF, et al. "Gabapentin for chronic neuropathic pain in adults." Cochrane Database of Systematic Reviews. 2017;6(6):CD007938. DOI
- Meaadi J, Obara I, Eldabe S, Nazar H. "The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials." International Journal of Clinical Pharmacy. 2023;45(3):556-565. DOI
- Medici V, McClave SA, Miller KR. "Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity." Current Gastroenterology Reports. 2016;18(1):2. DOI
- Kaye AD, Cassagne G, Abbott BM, et al. "Emerging Clinical Roles of Gabapentin and Adverse Effects, Including Weight Gain, Obesity, Depression, Suicidal Thoughts and Increased Risk of Opioid-Related Overdose and Respiratory Depression: A Narrative Review." Current Pain and Headache Reports. 2025;29(1):45. DOI
- Scott AJ, Correa AB, Bisby MA, et al. "Cognitive Behavioral Therapy for Insomnia in People With Chronic Disease: A Systematic Review and Meta-Analysis." JAMA Internal Medicine. 2025. DOI
Frequently Asked Questions
Common Questions
Deep-Dive Questions
Ready when you are
The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.


